Изменения
On 26 июня 2026 г., 16:37:44 UTC,
-
No fields were updated. See the metadata diff for more details.
| f | 1 | { | f | 1 | { |
| 2 | "author": "Ketalar Ketamine HCL", | 2 | "author": "Ketalar Ketamine HCL", | ||
| 3 | "author_email": "inquiries.lyfeunit@proton.me", | 3 | "author_email": "inquiries.lyfeunit@proton.me", | ||
| 4 | "creator_user_id": "5ecc116b-5ec4-48f4-8366-afe5052790b1", | 4 | "creator_user_id": "5ecc116b-5ec4-48f4-8366-afe5052790b1", | ||
| 5 | "extras": [], | 5 | "extras": [], | ||
| 6 | "groups": [], | 6 | "groups": [], | ||
| 7 | "id": "4f671f6b-13c1-4213-b78c-264392da29b2", | 7 | "id": "4f671f6b-13c1-4213-b78c-264392da29b2", | ||
| 8 | "isopen": false, | 8 | "isopen": false, | ||
| 9 | "license_id": "", | 9 | "license_id": "", | ||
| 10 | "license_title": "", | 10 | "license_title": "", | ||
| 11 | "maintainer": "", | 11 | "maintainer": "", | ||
| 12 | "maintainer_email": "", | 12 | "maintainer_email": "", | ||
| 13 | "metadata_created": "2026-06-26T16:36:51.401940", | 13 | "metadata_created": "2026-06-26T16:36:51.401940", | ||
| n | 14 | "metadata_modified": "2026-06-26T16:37:44.365410", | n | 14 | "metadata_modified": "2026-06-26T16:37:44.537219", |
| 15 | "name": | 15 | "name": | ||
| 16 | -ketamine-hcl-injection-usp-500mg-10ml-multi-dose-vial-clinical-data", | 16 | -ketamine-hcl-injection-usp-500mg-10ml-multi-dose-vial-clinical-data", | ||
| 17 | "notes": "This dataset provides a comprehensive technical and | 17 | "notes": "This dataset provides a comprehensive technical and | ||
| 18 | clinical profile of Ketalar (Ketamine HCl) Injection USP, the gold | 18 | clinical profile of Ketalar (Ketamine HCl) Injection USP, the gold | ||
| 19 | standard for rapid-acting, non-barbiturate general anesthesia. Each | 19 | standard for rapid-acting, non-barbiturate general anesthesia. Each | ||
| 20 | 10ml multi-dose vial contains 500mg of USP-grade Ketamine | 20 | 10ml multi-dose vial contains 500mg of USP-grade Ketamine | ||
| 21 | Hydrochloride (50mg/mL), formulated to ensure profound analgesia and | 21 | Hydrochloride (50mg/mL), formulated to ensure profound analgesia and | ||
| 22 | stable hemodynamics. This data is essential for researchers at NIASRA | 22 | stable hemodynamics. This data is essential for researchers at NIASRA | ||
| 23 | and the University of Wollongong (UOW) focused on emergency medicine, | 23 | and the University of Wollongong (UOW) focused on emergency medicine, | ||
| 24 | pediatric anesthesia, and NMDA receptor antagonism.\r\n\r\nTechnical | 24 | pediatric anesthesia, and NMDA receptor antagonism.\r\n\r\nTechnical | ||
| 25 | Specifications\r\n\t\u2022\tBrand: | 25 | Specifications\r\n\t\u2022\tBrand: | ||
| 26 | Ketalar\u00ae\r\n\t\u2022\tConcentration: 50mg/mL (500mg per 10ml | 26 | Ketalar\u00ae\r\n\t\u2022\tConcentration: 50mg/mL (500mg per 10ml | ||
| 27 | Multi-Dose Vial)\r\n\t\u2022\tCAS Number: | 27 | Multi-Dose Vial)\r\n\t\u2022\tCAS Number: | ||
| 28 | 1867-66-9\r\n\t\u2022\tRegulatory Status: CIII Controlled Substance | 28 | 1867-66-9\r\n\t\u2022\tRegulatory Status: CIII Controlled Substance | ||
| 29 | (DEA Schedule III)\r\n\t\u2022\tpH Range: 3.5 \u2013 5.5 (Sterile, | 29 | (DEA Schedule III)\r\n\t\u2022\tpH Range: 3.5 \u2013 5.5 (Sterile, | ||
| 30 | slightly acidic solution)\r\n\t\u2022\tPreservative: 0.1 mg/mL | 30 | slightly acidic solution)\r\n\t\u2022\tPreservative: 0.1 mg/mL | ||
| 31 | Benzethonium Chloride\r\n\r\nClinical & Research | 31 | Benzethonium Chloride\r\n\r\nClinical & Research | ||
| 32 | Applications\r\n\t\u2022\tGeneral Anesthesia Induction: Investigating | 32 | Applications\r\n\t\u2022\tGeneral Anesthesia Induction: Investigating | ||
| 33 | rapid-onset protocols for surgical procedures and trauma-related | 33 | rapid-onset protocols for surgical procedures and trauma-related | ||
| 34 | interventions.\r\n\t\u2022\tNMDA Receptor Antagonism: Exploring the | 34 | interventions.\r\n\t\u2022\tNMDA Receptor Antagonism: Exploring the | ||
| 35 | \u201cdissociative\u201d state produced by blocking excitatory | 35 | \u201cdissociative\u201d state produced by blocking excitatory | ||
| 36 | glutamate effects in the thalamocortical | 36 | glutamate effects in the thalamocortical | ||
| 37 | system.\r\n\t\u2022\tPediatric Anesthesia: Analyzing the safety | 37 | system.\r\n\t\u2022\tPediatric Anesthesia: Analyzing the safety | ||
| 38 | profile of ketamine for minor surgical procedures where respiratory | 38 | profile of ketamine for minor surgical procedures where respiratory | ||
| 39 | drive maintenance is critical.\r\n\t\u2022\tDiagnostic Sedation: | 39 | drive maintenance is critical.\r\n\t\u2022\tDiagnostic Sedation: | ||
| 40 | Studying its use as a sole agent for procedures not requiring skeletal | 40 | Studying its use as a sole agent for procedures not requiring skeletal | ||
| 41 | muscle relaxation (e.g., dental extractions, eye/ear | 41 | muscle relaxation (e.g., dental extractions, eye/ear | ||
| 42 | surgery).\r\n\r\nPharmacokinetics & Safety | 42 | surgery).\r\n\r\nPharmacokinetics & Safety | ||
| 43 | Data\r\n\t\u2022\tRedistribution Dynamics: Documenting the rapid | 43 | Data\r\n\t\u2022\tRedistribution Dynamics: Documenting the rapid | ||
| 44 | distribution into highly vascularized tissues (brain/heart) followed | 44 | distribution into highly vascularized tissues (brain/heart) followed | ||
| 45 | by muscle and adipose tissue.\r\n\t\u2022\tMetabolic Pathways: | 45 | by muscle and adipose tissue.\r\n\t\u2022\tMetabolic Pathways: | ||
| 46 | Analyzing hepatic N-demethylation to the active metabolite | 46 | Analyzing hepatic N-demethylation to the active metabolite | ||
| 47 | norketamine.\r\n\t\u2022\tEmergence Phenomena: Researching the | 47 | norketamine.\r\n\t\u2022\tEmergence Phenomena: Researching the | ||
| 48 | minimization of recovery-phase delirium through controlled | 48 | minimization of recovery-phase delirium through controlled | ||
| 49 | environments and co-administration strategies.\r\n\r\nSource | 49 | environments and co-administration strategies.\r\n\r\nSource | ||
| 50 | Information\r\nFor authoritative clinical data and professional-grade | 50 | Information\r\nFor authoritative clinical data and professional-grade | ||
| 51 | procurement, | 51 | procurement, | ||
| 52 | /lyfeunit.com/product/ketalar-ketamine-hcl-injection-usp-500mg-10ml/", | 52 | /lyfeunit.com/product/ketalar-ketamine-hcl-injection-usp-500mg-10ml/", | ||
| 53 | "num_resources": 1, | 53 | "num_resources": 1, | ||
| 54 | "num_tags": 14, | 54 | "num_tags": 14, | ||
| 55 | "organization": null, | 55 | "organization": null, | ||
| 56 | "owner_org": null, | 56 | "owner_org": null, | ||
| 57 | "private": false, | 57 | "private": false, | ||
| 58 | "relationships_as_object": [], | 58 | "relationships_as_object": [], | ||
| 59 | "relationships_as_subject": [], | 59 | "relationships_as_subject": [], | ||
| 60 | "resources": [ | 60 | "resources": [ | ||
| 61 | { | 61 | { | ||
| 62 | "cache_last_updated": null, | 62 | "cache_last_updated": null, | ||
| 63 | "cache_url": null, | 63 | "cache_url": null, | ||
| 64 | "created": "2026-06-26T16:37:44.388211", | 64 | "created": "2026-06-26T16:37:44.388211", | ||
| 65 | "datastore_active": false, | 65 | "datastore_active": false, | ||
| 66 | "description": "This dataset captures the clinical heritage and | 66 | "description": "This dataset captures the clinical heritage and | ||
| 67 | technical specifications of Ketalar (Ketamine HCl) Injection USP | 67 | technical specifications of Ketalar (Ketamine HCl) Injection USP | ||
| 68 | (500mg/10ml). As a cornerstone of modern anesthesia, Ketalar provides | 68 | (500mg/10ml). As a cornerstone of modern anesthesia, Ketalar provides | ||
| 69 | \u201ctechnical proof\u201d of efficacy through its unique ability to | 69 | \u201ctechnical proof\u201d of efficacy through its unique ability to | ||
| 70 | maintain cardiovascular stability and protective airway reflexes. The | 70 | maintain cardiovascular stability and protective airway reflexes. The | ||
| 71 | dataset is meticulously curated to meet the analytical standards of | 71 | dataset is meticulously curated to meet the analytical standards of | ||
| 72 | the National Institute for Applied Statistics Research Australia | 72 | the National Institute for Applied Statistics Research Australia | ||
| 73 | (NIASRA) and the University of Wollongong (UOW).\r\n\r\nClinical & | 73 | (NIASRA) and the University of Wollongong (UOW).\r\n\r\nClinical & | ||
| 74 | Technical Significance\r\nThe information detailed in this dataset is | 74 | Technical Significance\r\nThe information detailed in this dataset is | ||
| 75 | pivotal for:\r\n\r\n\t\u2022\tSympathomimetic Analysis: Understanding | 75 | pivotal for:\r\n\r\n\t\u2022\tSympathomimetic Analysis: Understanding | ||
| 76 | how Ketalar stimulates the cardiovascular system, making it ideal for | 76 | how Ketalar stimulates the cardiovascular system, making it ideal for | ||
| 77 | hemodynamically sensitive patients.\r\n\t\u2022\tPharmacokinetic | 77 | hemodynamically sensitive patients.\r\n\t\u2022\tPharmacokinetic | ||
| 78 | Modeling: Providing data on the redistribution and metabolism of the | 78 | Modeling: Providing data on the redistribution and metabolism of the | ||
| 79 | hydrochloride salt for accurate clinical | 79 | hydrochloride salt for accurate clinical | ||
| 80 | timing.\r\n\t\u2022\tProcedural Flexibility: Evaluating the benefits | 80 | timing.\r\n\t\u2022\tProcedural Flexibility: Evaluating the benefits | ||
| 81 | of a multi-dose vial optimized for both intravenous (IV) and | 81 | of a multi-dose vial optimized for both intravenous (IV) and | ||
| 82 | intramuscular (IM) administration.\r\n", | 82 | intramuscular (IM) administration.\r\n", | ||
| 83 | "format": "JPEG", | 83 | "format": "JPEG", | ||
| 84 | "hash": "", | 84 | "hash": "", | ||
| 85 | "id": "1449fac0-2b48-4fea-a64e-0cd8f0ec08d6", | 85 | "id": "1449fac0-2b48-4fea-a64e-0cd8f0ec08d6", | ||
| 86 | "last_modified": "2026-06-26T16:37:44.360459", | 86 | "last_modified": "2026-06-26T16:37:44.360459", | ||
| n | 87 | "metadata_modified": "2026-06-26T16:37:44.372118", | n | 87 | "metadata_modified": "2026-06-26T16:37:44.540360", |
| 88 | "mimetype": "image/jpeg", | 88 | "mimetype": "image/jpeg", | ||
| 89 | "mimetype_inner": null, | 89 | "mimetype_inner": null, | ||
| 90 | "name": "Ketalar (Ketamine HCl) Injection USP 500mg/10ml | 90 | "name": "Ketalar (Ketamine HCl) Injection USP 500mg/10ml | ||
| 91 | Research Data", | 91 | Research Data", | ||
| 92 | "package_id": "4f671f6b-13c1-4213-b78c-264392da29b2", | 92 | "package_id": "4f671f6b-13c1-4213-b78c-264392da29b2", | ||
| 93 | "position": 0, | 93 | "position": 0, | ||
| 94 | "resource_type": null, | 94 | "resource_type": null, | ||
| 95 | "size": 22648, | 95 | "size": 22648, | ||
| 96 | "state": "active", | 96 | "state": "active", | ||
| 97 | "url": | 97 | "url": | ||
| 98 | c08d6/download/ketalar-ketamine-hcl-injection-500mg10ml-400x400.jpeg", | 98 | c08d6/download/ketalar-ketamine-hcl-injection-500mg10ml-400x400.jpeg", | ||
| 99 | "url_type": "upload" | 99 | "url_type": "upload" | ||
| 100 | } | 100 | } | ||
| 101 | ], | 101 | ], | ||
| t | 102 | "state": "draft", | t | 102 | "state": "active", |
| 103 | "tags": [ | 103 | "tags": [ | ||
| 104 | { | 104 | { | ||
| 105 | "display_name": "500mg 10ml", | 105 | "display_name": "500mg 10ml", | ||
| 106 | "id": "f0dd1837-4de3-4d32-b7e9-e0f20cced044", | 106 | "id": "f0dd1837-4de3-4d32-b7e9-e0f20cced044", | ||
| 107 | "name": "500mg 10ml", | 107 | "name": "500mg 10ml", | ||
| 108 | "state": "active", | 108 | "state": "active", | ||
| 109 | "vocabulary_id": null | 109 | "vocabulary_id": null | ||
| 110 | }, | 110 | }, | ||
| 111 | { | 111 | { | ||
| 112 | "display_name": "Anesthesia Induction", | 112 | "display_name": "Anesthesia Induction", | ||
| 113 | "id": "890a493a-cc7d-4449-a3c1-1f093ab38ee0", | 113 | "id": "890a493a-cc7d-4449-a3c1-1f093ab38ee0", | ||
| 114 | "name": "Anesthesia Induction", | 114 | "name": "Anesthesia Induction", | ||
| 115 | "state": "active", | 115 | "state": "active", | ||
| 116 | "vocabulary_id": null | 116 | "vocabulary_id": null | ||
| 117 | }, | 117 | }, | ||
| 118 | { | 118 | { | ||
| 119 | "display_name": "CIII Controlled Substance", | 119 | "display_name": "CIII Controlled Substance", | ||
| 120 | "id": "586c6aa7-a775-4865-b199-0d0ab48d280f", | 120 | "id": "586c6aa7-a775-4865-b199-0d0ab48d280f", | ||
| 121 | "name": "CIII Controlled Substance", | 121 | "name": "CIII Controlled Substance", | ||
| 122 | "state": "active", | 122 | "state": "active", | ||
| 123 | "vocabulary_id": null | 123 | "vocabulary_id": null | ||
| 124 | }, | 124 | }, | ||
| 125 | { | 125 | { | ||
| 126 | "display_name": "Data", | 126 | "display_name": "Data", | ||
| 127 | "id": "e0872c47-a8dc-4845-9d19-7cf661eb6120", | 127 | "id": "e0872c47-a8dc-4845-9d19-7cf661eb6120", | ||
| 128 | "name": "Data", | 128 | "name": "Data", | ||
| 129 | "state": "active", | 129 | "state": "active", | ||
| 130 | "vocabulary_id": null | 130 | "vocabulary_id": null | ||
| 131 | }, | 131 | }, | ||
| 132 | { | 132 | { | ||
| 133 | "display_name": "Diagnostic Sedation", | 133 | "display_name": "Diagnostic Sedation", | ||
| 134 | "id": "654d220e-b56d-476e-91c1-a206b44ec28d", | 134 | "id": "654d220e-b56d-476e-91c1-a206b44ec28d", | ||
| 135 | "name": "Diagnostic Sedation", | 135 | "name": "Diagnostic Sedation", | ||
| 136 | "state": "active", | 136 | "state": "active", | ||
| 137 | "vocabulary_id": null | 137 | "vocabulary_id": null | ||
| 138 | }, | 138 | }, | ||
| 139 | { | 139 | { | ||
| 140 | "display_name": "Dissociative Anesthetic", | 140 | "display_name": "Dissociative Anesthetic", | ||
| 141 | "id": "e7a7397b-e7f6-4645-8d9a-c65108309ecb", | 141 | "id": "e7a7397b-e7f6-4645-8d9a-c65108309ecb", | ||
| 142 | "name": "Dissociative Anesthetic", | 142 | "name": "Dissociative Anesthetic", | ||
| 143 | "state": "active", | 143 | "state": "active", | ||
| 144 | "vocabulary_id": null | 144 | "vocabulary_id": null | ||
| 145 | }, | 145 | }, | ||
| 146 | { | 146 | { | ||
| 147 | "display_name": "Ketalar", | 147 | "display_name": "Ketalar", | ||
| 148 | "id": "591e4451-6521-4c4d-87b4-1d3b8bb1f7c8", | 148 | "id": "591e4451-6521-4c4d-87b4-1d3b8bb1f7c8", | ||
| 149 | "name": "Ketalar", | 149 | "name": "Ketalar", | ||
| 150 | "state": "active", | 150 | "state": "active", | ||
| 151 | "vocabulary_id": null | 151 | "vocabulary_id": null | ||
| 152 | }, | 152 | }, | ||
| 153 | { | 153 | { | ||
| 154 | "display_name": "Ketamine HCl", | 154 | "display_name": "Ketamine HCl", | ||
| 155 | "id": "5e098923-ccd9-48f0-baea-6379fceae81a", | 155 | "id": "5e098923-ccd9-48f0-baea-6379fceae81a", | ||
| 156 | "name": "Ketamine HCl", | 156 | "name": "Ketamine HCl", | ||
| 157 | "state": "active", | 157 | "state": "active", | ||
| 158 | "vocabulary_id": null | 158 | "vocabulary_id": null | ||
| 159 | }, | 159 | }, | ||
| 160 | { | 160 | { | ||
| 161 | "display_name": "NIASRA", | 161 | "display_name": "NIASRA", | ||
| 162 | "id": "1b4af2e3-493f-4ee9-bfbc-30d31a49f0bf", | 162 | "id": "1b4af2e3-493f-4ee9-bfbc-30d31a49f0bf", | ||
| 163 | "name": "NIASRA", | 163 | "name": "NIASRA", | ||
| 164 | "state": "active", | 164 | "state": "active", | ||
| 165 | "vocabulary_id": null | 165 | "vocabulary_id": null | ||
| 166 | }, | 166 | }, | ||
| 167 | { | 167 | { | ||
| 168 | "display_name": "NMDA Antagonist", | 168 | "display_name": "NMDA Antagonist", | ||
| 169 | "id": "a63f032f-29d9-4d47-9122-7161fecfb948", | 169 | "id": "a63f032f-29d9-4d47-9122-7161fecfb948", | ||
| 170 | "name": "NMDA Antagonist", | 170 | "name": "NMDA Antagonist", | ||
| 171 | "state": "active", | 171 | "state": "active", | ||
| 172 | "vocabulary_id": null | 172 | "vocabulary_id": null | ||
| 173 | }, | 173 | }, | ||
| 174 | { | 174 | { | ||
| 175 | "display_name": "Pediatric Anesthesia", | 175 | "display_name": "Pediatric Anesthesia", | ||
| 176 | "id": "bdb1ad8d-4999-44db-b973-5f5efffa2f80", | 176 | "id": "bdb1ad8d-4999-44db-b973-5f5efffa2f80", | ||
| 177 | "name": "Pediatric Anesthesia", | 177 | "name": "Pediatric Anesthesia", | ||
| 178 | "state": "active", | 178 | "state": "active", | ||
| 179 | "vocabulary_id": null | 179 | "vocabulary_id": null | ||
| 180 | }, | 180 | }, | ||
| 181 | { | 181 | { | ||
| 182 | "display_name": "Pharmacology", | 182 | "display_name": "Pharmacology", | ||
| 183 | "id": "7b8a5e22-8b54-44a8-97e6-0fb830dde386", | 183 | "id": "7b8a5e22-8b54-44a8-97e6-0fb830dde386", | ||
| 184 | "name": "Pharmacology", | 184 | "name": "Pharmacology", | ||
| 185 | "state": "active", | 185 | "state": "active", | ||
| 186 | "vocabulary_id": null | 186 | "vocabulary_id": null | ||
| 187 | }, | 187 | }, | ||
| 188 | { | 188 | { | ||
| 189 | "display_name": "UOW", | 189 | "display_name": "UOW", | ||
| 190 | "id": "db7fb5f3-4f8e-45eb-ac60-18d37318f122", | 190 | "id": "db7fb5f3-4f8e-45eb-ac60-18d37318f122", | ||
| 191 | "name": "UOW", | 191 | "name": "UOW", | ||
| 192 | "state": "active", | 192 | "state": "active", | ||
| 193 | "vocabulary_id": null | 193 | "vocabulary_id": null | ||
| 194 | }, | 194 | }, | ||
| 195 | { | 195 | { | ||
| 196 | "display_name": "USP Grade", | 196 | "display_name": "USP Grade", | ||
| 197 | "id": "a6ff46c0-e9d0-4a0a-a2e1-029ff59797a4", | 197 | "id": "a6ff46c0-e9d0-4a0a-a2e1-029ff59797a4", | ||
| 198 | "name": "USP Grade", | 198 | "name": "USP Grade", | ||
| 199 | "state": "active", | 199 | "state": "active", | ||
| 200 | "vocabulary_id": null | 200 | "vocabulary_id": null | ||
| 201 | } | 201 | } | ||
| 202 | ], | 202 | ], | ||
| 203 | "title": "Ketalar (Ketamine HCl) Injection USP 500mg/10ml: Clinical | 203 | "title": "Ketalar (Ketamine HCl) Injection USP 500mg/10ml: Clinical | ||
| 204 | Data for Anesthesia Induction & Sedation", | 204 | Data for Anesthesia Induction & Sedation", | ||
| 205 | "type": "dataset", | 205 | "type": "dataset", | ||
| 206 | "url": | 206 | "url": | ||
| 207 | /lyfeunit.com/product/ketalar-ketamine-hcl-injection-usp-500mg-10ml/", | 207 | /lyfeunit.com/product/ketalar-ketamine-hcl-injection-usp-500mg-10ml/", | ||
| 208 | "version": "" | 208 | "version": "" | ||
| 209 | } | 209 | } |